NCT04514419View on ClinicalTrials.gov

Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

PHASE3UnknownINTERVENTIONAL
Enrollment

408

Participants

Timeline

Start Date

June 30, 2020

Primary Completion Date

November 20, 2021

Study Completion Date

November 20, 2021

Conditions
Breast Cancer
Interventions
DRUG

HS627

Prior to surgery: trastuzumab, HS627, and docetaxel for 4 cycles (1 cycle = 21 days).

DRUG

Pertuzumab

Prior to surgery: trastuzumab, Pertuzumab, and docetaxel for 4 cycles (1 cycle = 21 days).

Trial Locations (1)

266000

RECRUITING

The Affiliated Hospital of Qingdao University, Qingdao

Sponsors
All Listed Sponsors
lead

BioRay Pharmaceutical Co., Ltd.

INDUSTRY